Results of DMSA Treatment Study

1
Results of DMSA Treatment Study

• James Adams, Liz Geis, Matthew Baral, Jessica
  Mitchell, Julie Ingram, Andrea Hensley, Sanford
  Newmark, Eva Gehn, Bob Rubin, Warren Tripp, Ken
  Mitchell, Jeff Bradstreet, Jane El-Dahr
• Southwest College of Naturopathic Medicine
• Funded by Wallace Foundation and
• Autism Research Institute

2
Current study

• Goal Determine if DMSA/glutathione therapy
  helps children with autism.
• Phase 1 9 doses of DMSA over 3 days, 10
  mg/kg-dose collect urine at baseline, after 1st
  dose, and after 9th dose daily doses of
  glutathione
• - if high toxic metal excretion, continue to
  phase 2
• Phase 2 3 month, double-blind, 1
  round-controlled treatment study
• 3 days on DMSA, 11 days off repeat 6x
• 82 children enrolled
• 65 completed phase 1
• 41 completed phase 2

3
Phase 1

• Started with 82 participants
• 1 did not qualify due to elevated liver enzymes
• 4 stopped after physical exam
• 11 stopped after initial blood draw (2 could not
  collect baseline urine)
• 1 collected urine after DMSA but did not send to
  lab (busy family)
• 65 collected urine after DMSA and sent to lab for
  testing

4
Toxic Metal Excretion after DMSA 1st 9th
dose changes in median values (N63)
5
Loss of essential minerals

• Potassium
• 1st dose lost 27 of RDA
• 9th dose lost 12 of RDA
• So 1st day probably lost about 75 of RDA, 2nd
  day about 55 of RDA, and 3rd day about 40 of
  RDA plt.0000000001
• Equivalent to loss of about 7 bananas worth of
  potassium over 3 days
• However, blood levels normal when tested 3-4
  weeks later, so no long-term effect
• Chromium 1st dose lose 45 of RDA 9th dose
  lose 15 of RDA p0.0005 so, several days of
  DMSA results in several days loss of chromium

6
Loss of essential minerals (cont.)

• Molybdenum decreased excretion by 6 on 1st
  day, 30 on 9th dose. Probably not a concern.
• Sodium 1st dose increased excretion of 30,
  normal by 9th dose not a concern
• Copper and Zinc Increased excretion, but less
  than 1 of RDA
• Vanadium small loss (about 1/3 of daily intake)
• Little change calcium, phosphorus, magnesium,
  sulfur, selenium
• Conclusion DMSA causes some loss of potassium
  and chromium, small loss of vanadium excretion
  of other minerals is unimportant
• Recommendation when using DMSA, eat extra
  fruits/vegetables for potassium (cannot
  supplement it), and supplement chromium and
  possibly vanadium.

7
Initial Glut 31-1033 - many lower/higher than
adult RR of 427-714 Final Glutathione 355-695
- almost all within reference range For low RBC
glutathione, DMSA greatly increased values to
normal For high RBC glutathione, DMSA reduced
values towards normal
8
Why are some RBC Glutathione unusually low and
high?

• Initial glutathione correlates with Pb-9 (.25),
  Sb-b (0.26), Cd-9 (0.30), Al-9 (0.29), and
  inversely correlates with Hg-9 (-.27).
• Hypothesis body responds to Pb, Sb, Cd, Al by
  making more glutathione. But, mercury blocks
  production of glutathione, and decreases it.

9
Why does 1 round of DMSA normalize glutathione?

• Change in glutathione correlates with Hg-9
  (0.31), and inversely correlates with W-9
  (-0.45) and Cd-9 (-0.47).
• So, removing some mercury increases low
  glutathione, and removing tungsten and cadmium
  reduces high glutathione.

10
Changes in Blood Chemistry after 1 round of DMSA
(measured 3-6 weeks later, n41)

• Major Tests no major problems, possible
  improvement of kidney function
• White Blood Cell -3
• Platelet Count -6, p0.02 (12/42 high, 1 low
  then 6/42 high, 0 low)
• Lymphocytes -4
• Potassium 1
• ALT (liver enzyme) 4
• AST (liver enzyme) 0
• BUN/creatinine -6, n.s. (17/42 high, 0 low,
  then 14/42 high, 1/42 low)
• Creatinine -2 (0 high, 8/42 low, then 0 high,
  9/42 low)
• Other changes (none were statistically
  significant)
• Basophils 24
• Bilirubin -15, n.s.
• Suggests no major safety concerns for 1 round
• Platelet levels improve (less inflammation)
• BUN/creatinine often high, since creatinine low,
  BUN high

11
Transition to Phase 2

• 8 children not allowed to continue due to low
  excretion of toxic metals
• 1 child not allowed to continue due to extremely
  high lead
• 1 family left on extended travel
• 1 family wanted to try other treatments
• 1 child discontinued due to extended use of
  antibiotics due to urinary tract infections
• 1 family too busy/overwhelmed
• 1 child had extreme anxiety over blood draws
• 1 wanted to start private treatment (avoid risk
  of placebo)
• 1 had mild adverse reactions (lethargy, increased
  appetite)
• 49 continued to Phase 2

12
Phase 2 Randomized, double-blind,
placebo-controlled

• 2 dropped due to family reasons (parents busy,
  parent died)
• 2 dropped due to lack of improvement
• 4 dropped due to behavior problems
• Mild slept very little, but not tired (on DMSA)
• Moderate behavior worsened, more stimming (on
  placebo)
• Moderate behavior worsening, regressing (on
  placebo)
• ???? parents reported gain and lose skills,
  similar pattern for 2 years prior to study, but
  ADOS scores improved (on DMSA)
• 41 finished full study, including 4 in treatment
  group who finished early due to low excretion
  after 3rd round

13
Long-term Effect of DMSA on Urinary Excretion of
Toxic Metals Changes in Median
ValuesTreatment Group Only (n26)
14
Summary of long-term metal excretion

• For 5 children, DMSA treatment resulted in
  substantial decrease in excretion of lead, so
  they were only treated for 3-4 rounds
• For most of the children receiving DMSA (19),
  lead excretion continued at a high level.
• Moderate excretion of mercury, tin, thallium.
• Al excretion initially decreased, then increased.

15
Changes in Blood Chemistry after 7 rounds of DMSA
n21

• No major problems platelets improved kidney
  function remains abnormal
• Platelets -18, p0.05
• (initially 10 high, 1 low to 4 high, 0 low
  improved!)
• White Blood Cell -7 n.s. (initially 1 high, 0
  low then 1 high, 1 low)
• Lymphocytes 0
• Potassium 0
• ALT (liver enzyme) 3 - initially 1 high, then
  all ok
• AST (liver enzyme) -6 - all normal
• BUN/creatinine (kidney) 8 - initially 10 high,
  then 9 high, 1 low
• Statistically Significant changes
• Triglycerides 47, p0.06 (trend) - initially
  zero high, then 2 high
• Other changes (not significant)
• Eosinophils -19, p0.08 3 high, then 2 high
• Basophils 50, n.s. - all normal
• Alkaline Phosphatase 12, n.s. all normal,
  then 5 high (growth spurt?)

16
Changes in blood chemistry after 1 round DMSA, 7
rounds placebo

• Platelets -13, p0.01 initially 1 high, then
  all normal measured 3-4 months after treatment,
  so effects are long-lasting
• Similar to 7 dose case (-18)
• Nothing else significant (no long-term effects
  safe)

17
Regression analysis of Platelets

• Change in platelet level could be partially
  explained (adjusted R20.41, p0.02) with major
  factors being excretion of Thallium (p0.002),
  Arsenic (p0.01), Cadmium (p0.03), and change in
  glutathione (p0.04)

18
Evaluations of Autism Symptoms

• Parents
• Severity of Autism Scale
• ATEC parents
• PDD-BI
• Global Impressions
• Research-certified professionals did ADOS

19
Severity of Autism Scale

• 0-10 point scale
• 7 round group -18 (improvement)
• 1-round group -18 (improvement)
• Significant improvement in both groups.

20
ATEC Results
Both groups significantly improved 7 round group
improved more in Language, Physical Health, and
Total ATEC, but not statistically significant
21
Pervasive Developmental Disorders Behavior
Inventory (PDD-BI)
Significant improvement in both groups
22
Overall Impressions - Results

• Based on parent evaluations on final day of study
• 7 point scale
• 3much better
• 2better
• 1slightly better
• 0same
• -1slightly worse
• -2worse
• -3much worse

23
Parent Global Impressions
24
Parent Impressions- Overall
25
ADOS exam

• Autism Diagnostic Observation Schedule
• Based on 1-hour standardized interaction with
  child by ADOS-certified professional
• One of the gold standards for evaluating
  severity of autism

26
ADOS results
7 rounds 1 round Communication -9 -11 Social
Interaction -10 -2 Play/Creativity -5 0 SBR
I (stereotyped behavior and restricted
interests) -9 -2
ADOS less sensitive than other instruments
(developed to diagnose autism, not monitor
changes). Overall, 7-round group improved
slightly more, but not significant difference
27
Summary of Autism Evaluations

• Significant improvements on all scales for both
  groups
• 7 dose group had slightly better improvements on
  ATEC and ADOS, but not statistically significant
• Similar improvements in PDD-BI, SAS, Global
  Impressions
• Since most kids still excreting high amounts of
  lead after 7 rounds, suggests longer treatment
  needed to reduce lead excretion.
• Question would longer treatments result in more
  behavioral improvements?

28
Why little difference between 7 rounds and 1
round?

• Hypothesis 1 DMSA ineffective on autism
  symptoms (placebo effect).
• Hypothesis 2 1st round of DMSA normalized
  glutathione and improved platelet levels, so that
  further treatment had little additional effect.
• Correlations of behavioral improvement with
  biochemical changes suggest hypothesis 2 is
  correct.

29
Overall change in autism severity, including both
7-round and 1-round groups

30
Regression Analysis Severity of Autism

• Compare severity of autism with glutathione and
  metal tests
• adjusted R2 Most significant metals
• ATEC 0.22 p0.003 Pb-9, Sb-b
• SAS 0.36 p0.002 Pb-b
• PDD-BI 0.25 p 0.004 Sb-9, W-b, Sn-9
  
• ADOS 0.49 p0.0003 Hg-b, Al-b, Hg-9
• All four scales of autism severity can be
  partially explained in terms of heavy metal
  excretion, with a very high statistical
  significance.
• Suggests 22-49 of autism severity appears to be
  due to toxic metals, especially lead, antimony,
  and mercury.

31
Regression Analysis Improvement

• Compare improvements in severity of autism with
  glutathione and metal tests
• adjusted R2 Most significant metals
• ATEC 0.44 p0.006 Hg-9, As-9
• SAS 0.57 p0.002 Tl-9, Pb-9, glut change
• PDD-BI 0.75 p0.0006 Tl-9, As-9, glut change,
  Pb-9, Sb-9
• ADOS 0.28 p0.02 As-9, Al-9
• Changes in all four scales can be partially
  explained (28-75) in terms of urinary excretion
  of metals
• Arsenic, thallium, lead, and change in
  glutathione are most important
• When glutathione increases, symptoms generally
  decrease.
• When metal excretion increases, symptoms
  generally decrease

32
Effect of Age on Improvement

• Slight negative correlation suggests that older
  children possibly tended to improve slightly more
  than younger children (not significant)
• Test Correlation with age
• ATEC -.20
• SAS -.19
• PDD-BI -.12
• ADOS -.06

33
(No Transcript)
34
Conclusions - benefits

• DMSA greatly increases excretion of lead, and
  some increase in excretion of tin, mercury,
  thallium.
• 1 round of DMSA dramatically normalized
  glutathione levels for at least 1-2 months, and
  helped normalize platelet levels (marker of
  inflammation) for at least 4 months

35
Conclusions - safety

• DMSA increases excretion of potassium and
  chromium suggests need for more vegetables/fruit
  and modest chromium supplementation during
  chelation
• DMSA had little effect on other essential
  minerals
• DMSA had no adverse effect on liver enzymes,
  kidney function, or complete blood count (CBC)
• DMSA possibly raised triglycerides concern to
  watch for
• Check cysteine levels, since 90 of DMSA is
  excreted bound to 1-2 cysteine.

36
Conclusions Effect on Symptoms

• Both groups had significant improvements on
  autism scores
• 7-round group had slightly more improvements on
  ATEC and ADOS, but not significant
• More improvement in those with low glutathione
  and high initial metal excretion strong
  correlations and regression analysis strongly
  suggest that improvement is real (not just
  placebo effect)

37
Bottom Line

• Toxic metals (especially lead, antimony, and
  mercury) account for 22-49 of autism severity.
• DMSA is a safe way to remove toxic metals,
  normalize glutathione, normalize
  platelets/inflammation
• Correlation of improvement in autistic symptoms
  with glutathione and metal excretion suggests
  DMSA did result in reduction of some symptoms of
  autism.
• Longer treatment needed by most children to
  decrease lead levels unknown if longer
  treatment might provide additional behavior
  benefit.
• Double-blind, placebo-controlled study of DMSA
  needed
• Other chelators may be needed for mercury and
  other metals (arsenic, antimony).
• More research should be done!

38
Questions

• Will longer treatment with DMSA result in more
  benefit?
• Probably, but need to study
• How to test for and remove antimony?
• DMPS, somewhat Ca-EDTA
• How to test for and remove mercury?
• DMPS challenge, urinary porphyrins, other

39
Acknowledgements

• Many children and parents who participated in the
  study
• ARI and Wallace Foundation for funding
• Doctors Data for urine testing
• Immunosciences for RBC glutathione and immune
  testing